Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein, conserved | 0.197 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1353 | 0.5122 | 0.5122 |
Loa Loa (eye worm) | hypothetical protein | 0.1521 | 0.6454 | 0.5891 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.1353 | 0.5122 | 0.4347 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.197 | 1 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0951 | 0.1947 | 0.1947 |
Toxoplasma gondii | kringle domain-containing protein | 0.197 | 1 | 0.5 |
Onchocerca volvulus | 0.197 | 1 | 1 | |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.197 | 1 | 0.5 |
Brugia malayi | Kringle domain containing protein | 0.197 | 1 | 1 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.197 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.197 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.197 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.197 | 1 | 1 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.197 | 1 | 1 |
Brugia malayi | Muscle positioning protein 4 | 0.1521 | 0.6454 | 0.2731 |
Loa Loa (eye worm) | hypothetical protein | 0.1353 | 0.5122 | 0.4347 |
Onchocerca volvulus | 0.1521 | 0.6454 | 0.2731 | |
Echinococcus granulosus | tissue type plasminogen activator | 0.197 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.